Vietnam’s investment minister visits AstraZeneca China

Dung visited the center’s laboratories and facilities. He also held discussions with AstraZeneca leaders on promoting innovation and scientific collaboration, facilitating research and experience exchange, attracting resources to leverage innovation, and attracting investment in high-tech, innovative healthcare projects.

The Vietnamese delegation on the day visited AstraZeneca China. Photo courtesy of AstraZeneca

Dung expressed his expectation that, with support from AstraZeneca and its partners, Vietnam could improve the operational efficiency of its innovation model in science, technology, and AI, particularly within healthcare.

According to the minister, the application of science, technology, and innovation across all sectors is a sustainable and effective pathway for Vietnam’s development.

“In particular, healthcare innovation plays a crucial role in disease prevention, detection, and diagnosis. The scale and modernity of AstraZeneca’s global R&D center and the wider innovation ecosystem it fosters serve as a prime example of successful investment cooperation between businesses and the state, offering valuable learnings that can be referenced for Vietnam’s innovation center,” he said.

Nitin Kapoor, Vice President of Biopharmaceutical International and Chairman of AstraZeneca Vietnam, shared at the delegation visit on March 30. Photo courtesy of AstraZeneca

According to Nitin Kapoor, Vice President of Biopharmaceutical International and Chairman of AstraZeneca Vietnam, for the past 30 years, the company has been a trusted partner in Vietnam’s healthcare development, striving to improve healthcare capacity and community health.

“Looking ahead, they commit to continued investment and knowledge sharing in digital applications, AI, and promoting healthcare transformation to enhance screening efficiency and early disease detection. This will ultimately reduce the burden on patients, families, and society,” he said.

In late 2023, together with the Vietnamese Young Physicians’ Association, AstraZeneca launched the “Healthcare Innovation Network,” and phase 1 focused on the “Digital Transformation for Lung Health” project, which has benefited over 100,000 people.

It serves as a significant leap for innovation in healthcare and digital/AI transformation.

Through collaboration with AstraZeneca, China has established a collaborative healthcare innovation ecosystem. This high-tech platform integrates various resources, fostering the incubation of innovative healthcare models and the development of new biological treatments alongside diagnostic and monitoring equipment for smart healthcare.